Applied DNA Sciences, Inc. (NASDAQ:APDN) Sees Large Drop in Short Interest

Applied DNA Sciences, Inc. (NASDAQ:APDN) was the target of a large drop in short interest during the month of October. As of October 15th, there was short interest totalling 853,200 shares, a drop of 51.0% from the September 30th total of 1,740,000 shares. Based on an average trading volume of 10,730,000 shares, the days-to-cover ratio is presently 0.1 days.

Hedge Funds Weigh In On Applied DNA Sciences

A hedge fund recently raised its stake in Applied DNA Sciences stock. AMH Equity Ltd raised its stake in shares of Applied DNA Sciences, Inc. (NASDAQ:APDN) by 46.1% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 540,385 shares of the technology company’s stock after purchasing an additional 170,385 shares during the period. AMH Equity Ltd owned 63.57% of Applied DNA Sciences worth $222,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 22.22% of the company’s stock.

Applied DNA Sciences Stock Performance

NASDAQ:APDN remained flat at $0.31 during trading hours on Friday. 2,131,723 shares of the company’s stock traded hands, compared to its average volume of 3,709,863. The stock has a market capitalization of $304,759.00, a P/E ratio of -0.02 and a beta of 0.34. Applied DNA Sciences has a twelve month low of $0.28 and a twelve month high of $22.80. The firm has a 50-day moving average of $1.08 and a 200 day moving average of $1.60.

Applied DNA Sciences (NASDAQ:APDN) last posted its quarterly earnings results on Thursday, August 8th. The technology company reported $0.47 EPS for the quarter, beating analysts’ consensus estimates of ($0.64) by $1.11. Applied DNA Sciences had a negative return on equity of 138.41% and a negative net margin of 214.42%. The business had revenue of $0.80 million for the quarter, compared to analysts’ expectations of $0.95 million. During the same period last year, the firm earned ($4.80) earnings per share. As a group, research analysts forecast that Applied DNA Sciences will post -1.8 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded Applied DNA Sciences to a “sell” rating in a research report on Tuesday, September 17th.

Applied DNA Sciences Company Profile

Applied DNA Sciences, Inc, a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services.